Literature DB >> 28708417

Association of Antibiotics, Airway Microbiome, and Inflammation in Infants with Cystic Fibrosis.

Jessica E Pittman1, Kristine M Wylie1,2, Kathryn Akers1, Gregory A Storch1, Joseph Hatch3, Jane Quante1, Katherine B Frayman4,5,6, Nadeene Clarke4,5,6, Miriam Davis3, Stephen M Stick7,8,9, Graham L Hall8,10,11, Gregory Montgomery3, Sarath Ranganathan4,5,6, Stephanie D Davis3, Thomas W Ferkol1,12.   

Abstract

RATIONALE: The underlying defect in the cystic fibrosis (CF) airway leads to defective mucociliary clearance and impaired bacterial killing, resulting in endobronchial infection and inflammation that contributes to progressive lung disease. Little is known about the respiratory microbiota in the early CF airway and its relationship to inflammation.
OBJECTIVES: To examine the bacterial microbiota and inflammatory profiles in bronchoalveolar lavage fluid and oropharyngeal secretions in infants with CF.
METHODS: Infants with CF from U.S. and Australian centers were enrolled in a prospective, observational study examining the bacterial microbiota and inflammatory profiles of the respiratory tract. Bacterial diversity and density (load) were measured. Lavage samples were analyzed for inflammatory markers (interleukin 8, unbound neutrophil elastase, and absolute neutrophil count) in the epithelial lining fluid.
RESULTS: Thirty-two infants (mean age, 4.7 months) underwent bronchoalveolar lavage and oropharyngeal sampling. Shannon diversity strongly correlated between upper and lower airway samples from a given subject, although community compositions differed. Microbial diversity was lower in younger subjects and in those receiving daily antistaphylococcal antibiotic prophylaxis. In lavage samples, reduced diversity correlated with lower interleukin 8 concentration and absolute neutrophil count.
CONCLUSIONS: In infants with CF, reduced bacterial diversity in the upper and lower airways was strongly associated with the use of prophylactic antibiotics and younger age at the time of sampling; less diversity in the lower airway correlated with lower inflammation on bronchoalveolar lavage. Our findings suggest modification of the respiratory microbiome in infants with CF may influence airway inflammation.

Entities:  

Keywords:  bacterial infection; cystic fibrosis; microbiota; pediatric lung disease inflammation; respiratory infection

Mesh:

Substances:

Year:  2017        PMID: 28708417      PMCID: PMC5718571          DOI: 10.1513/AnnalsATS.201702-121OC

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN: 2325-6621


  31 in total

Review 1.  Cystic fibrosis: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases.

Authors:  Jessica E Pittman; Garry Cutting; Stephanie D Davis; Thomas Ferkol; Richard Boucher
Journal:  Ann Am Thorac Soc       Date:  2014-04

Review 2.  The changing microbial epidemiology in cystic fibrosis.

Authors:  John J Lipuma
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

3.  Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis.

Authors:  Zhanhai Li; Michael R Kosorok; Philip M Farrell; Anita Laxova; Susan E H West; Christopher G Green; Jannette Collins; Michael J Rock; Mark L Splaingard
Journal:  JAMA       Date:  2005-02-02       Impact factor: 56.272

4.  Quantitative analysis of the human airway microbial ecology reveals a pervasive signature for cystic fibrosis.

Authors:  Paul C Blainey; Carlos E Milla; David N Cornfield; Stephen R Quake
Journal:  Sci Transl Med       Date:  2012-09-26       Impact factor: 17.956

Review 5.  The importance of the development of the intestinal microbiota in infancy.

Authors:  Carl Vael; Kristine Desager
Journal:  Curr Opin Pediatr       Date:  2009-12       Impact factor: 2.856

Review 6.  Emerging cystic fibrosis pathogens and the microbiome.

Authors:  Eshwar Mahenthiralingam
Journal:  Paediatr Respir Rev       Date:  2014-04-13       Impact factor: 2.726

7.  Evaluation of 16S rDNA-based community profiling for human microbiome research.

Authors: 
Journal:  PLoS One       Date:  2012-06-13       Impact factor: 3.240

8.  Lung microbiota across age and disease stage in cystic fibrosis.

Authors:  Bryan Coburn; Pauline W Wang; Julio Diaz Caballero; Shawn T Clark; Vijaya Brahma; Sylva Donaldson; Yu Zhang; Anu Surendra; Yunchen Gong; D Elizabeth Tullis; Yvonne C W Yau; Valerie J Waters; David M Hwang; David S Guttman
Journal:  Sci Rep       Date:  2015-05-14       Impact factor: 4.379

9.  The microbial community of the cystic fibrosis airway is disrupted in early life.

Authors:  Julie Renwick; Paul McNally; Bettina John; Todd DeSantis; Barry Linnane; Philip Murphy
Journal:  PLoS One       Date:  2014-12-19       Impact factor: 3.240

10.  Statistical methods for detecting differentially abundant features in clinical metagenomic samples.

Authors:  James Robert White; Niranjan Nagarajan; Mihai Pop
Journal:  PLoS Comput Biol       Date:  2009-04-10       Impact factor: 4.475

View more
  24 in total

1.  Journal Club - Bronchiectasis/COPD Overlap: Syndrome Versus Treatable Trait?

Authors:  Ron Balkissoon
Journal:  Chronic Obstr Pulm Dis       Date:  2019-04

2.  CrossTalk opposing view: mucosal acidification does not drive early progressive lung disease in cystic fibrosis.

Authors:  Stephen M Stick; André Schultz
Journal:  J Physiol       Date:  2018-07-17       Impact factor: 5.182

Review 3.  Cystic fibrosis respiratory microbiota: unraveling complexity to inform clinical practice.

Authors:  Lindsay J Caverly; John J LiPuma
Journal:  Expert Rev Respir Med       Date:  2018-09-03       Impact factor: 3.772

4.  Mucus accumulation in the lungs precedes structural changes and infection in children with cystic fibrosis.

Authors:  Charles R Esther; Marianne S Muhlebach; Camille Ehre; David B Hill; Matthew C Wolfgang; Mehmet Kesimer; Kathryn A Ramsey; Matthew R Markovetz; Ian C Garbarine; M Gregory Forest; Ian Seim; Bryan Zorn; Cameron B Morrison; Martial F Delion; William R Thelin; Diane Villalon; Juan R Sabater; Lidija Turkovic; Sarath Ranganathan; Stephen M Stick; Richard C Boucher
Journal:  Sci Transl Med       Date:  2019-04-03       Impact factor: 17.956

5.  Differences in the lower airway microbiota of infants with and without cystic fibrosis.

Authors:  Katherine B Frayman; Kristine M Wylie; David S Armstrong; Rosemary Carzino; Stephanie D Davis; Thomas W Ferkol; Keith Grimwood; Gregory A Storch; Sarath C Ranganathan
Journal:  J Cyst Fibros       Date:  2018-12-21       Impact factor: 5.482

6.  Age and environmental exposures influence the fecal bacteriome of young children with cystic fibrosis.

Authors:  Brett R Loman; Chandra L Shrestha; Rohan Thompson; Judith A Groner; Asuncion Mejias; Kathryn L Ruoff; George A O'Toole; Michael T Bailey; Benjamin T Kopp
Journal:  Pediatr Pulmonol       Date:  2020-04-10

7.  Mucoid Pseudomonas aeruginosa and regional inflammation in the cystic fibrosis lung.

Authors:  Sankalp Malhotra; Don Hayes; Daniel J Wozniak
Journal:  J Cyst Fibros       Date:  2019-04-26       Impact factor: 5.482

Review 8.  Cystic Fibrosis and Pseudomonas aeruginosa: the Host-Microbe Interface.

Authors:  Sankalp Malhotra; Don Hayes; Daniel J Wozniak
Journal:  Clin Microbiol Rev       Date:  2019-05-29       Impact factor: 26.132

9.  Elastase Exocytosis by Airway Neutrophils Is Associated with Early Lung Damage in Children with Cystic Fibrosis.

Authors:  Camilla Margaroli; Luke W Garratt; Hamed Horati; A Susanne Dittrich; Timothy Rosenow; Samuel T Montgomery; Dario L Frey; Milton R Brown; Carsten Schultz; Lokesh Guglani; Anthony Kicic; Limin Peng; Bob J Scholte; Marcus A Mall; Hettie M Janssens; Stephen M Stick; Rabindra Tirouvanziam
Journal:  Am J Respir Crit Care Med       Date:  2019-04-01       Impact factor: 21.405

10.  Lung inflammation and simulated airway resistance in infants with cystic fibrosis.

Authors:  Emily M DeBoer; Julia S Kimbell; Kaci Pickett; Joseph E Hatch; Kathryn Akers; John Brinton; Graham L Hall; Louise King; Fiona Ramanauskas; Tim Rosenow; Stephen M Stick; Harm A Tiddens; Thomas W Ferkol; Sarath C Ranganathan; Stephanie D Davis
Journal:  Respir Physiol Neurobiol       Date:  2021-06-19       Impact factor: 1.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.